Janssen picks up AC Immune's Alzheimer's vaccine
This article was originally published in Scrip
AC Immune has signed a license agreement with Johnson and Johnson subsidiary Janssen, worth a potential $509m, to develop its Alzheimer's disease vaccine candidates.
You may also be interested in...
Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Grifols-Backed Biotech Sees Early Promise With Alzheimer's Vaccine
Phase I results for Araclon Biotech's Alzheimer's disease vaccine, ABvac40 – the only vaccine data presented at this year's Alzheimer's Association International Conference – warrant further exploration of this innovative approach to the disease.